Printer Friendly

Engaging patients to support adherence.

LATUDA is indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of LATUDA was established in a 6-week monotherapy study and a 6-week adjunctive therapy study with lithium or valproate in adult patients with bipolar depression. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established.

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years.

A multidisciplinary panel of Clinical Experts contributed to the development of this 3-part newsletter series. Each issue explores strategies for the management of patients with bipolar disorder and features expert commentary from the psychiatry, primary care, or nurse-practitioner/ physician-assistant perspective.

The Issue of Nonadherence in Bipolar Disorder

Nonadherence to psychiatric medication is one of the main clinical challenges in the treatment of individuals with bipolar disorder. A recent cross-sectional study of 303 outpatients with the illness found that 69.3% had suboptimal adherence. (1) In multivariate analyses, depressive polarity of the last episode, current acute episode, presence of subsyndromal symptoms, and substance use or dependence emerged as predictors of poor treatment adherence. (1) Notably, patients with bipolar disorder spend the majority of their symptomatic time--68% in 1 study--experiencing depressive symptoms, and the lifetime rate of comorbid substance use disorder in this population is 48%, suggesting that several of the factors that predict poor adherence predominate the bipolar disorder clinical picture. (2,3)

The consequences of nonadherence in this patient population include increased total medical expenditures and outpatient mental health care costs due to greater risk for symptom exacerbation and recurrence, as well as lower treatment effectiveness and poorer treatment outcomes. (4) Several studies have found that patients with poor adherence also experience worse functional outcomes. (1)

The effect of poor adherence to psychiatric medication may extend beyond a patient's mental health. In a recent study, Levin and colleagues found that greater depression severity--particularly the presence of vegetative symptoms and retardation--was significantly correlated with poor adherence to nonpsychiatric medication (P=.011 and P=.005, respectively), based on the Tablets Routine Questionnaire. (5) This finding is noteworthy because it demonstrates that nonadherence to psychiatric medication may cascade into nonadherence to medication for the treatment of medical comorbidities that are prevalent in patients with bipolar disorder. (6)

Barriers to adherence in patients with bipolar disorder include both intentional factors (eg, anosognosia, or limited insight or lack of awareness about having a psychiatric disorder, and dislike of or concerns about side effects) and unintentional factors (eg, forgetting to take medication, possibly due to executive functioning deficits and lack of routines). External factors, such as financial problems, high cost of medication, lack of health insurance coverage, and poor relationships with health care professionals, may contribute to nonadherence. (4,8) Internal factors, such as lack of symptoms during euthymia and, in some cases, pleasure from the high energy and increased self-esteem experienced during mania, can make it difficult for patients with bipolar disorder to adhere to treatment regimens. (4) Furthermore, taking medication can reinforce for patients and family members the stigma frequently associated with mental illness. (4) The reasons for nonadherence are multifactorial and may transcend the individual patient. It is important for health care professionals to appreciate their role in treatment adherence, starting with a strong therapeutic alliance with their patients. (8)

Strategies to Motivate Treatment Adherence

Several strategies that can be employed by the multidisciplinary care team may improve adherence in patients with bipolar disorder. One strategy--motivational interviewing--involves a deeply humanistic approach to actively hearing patients' own motivations for change and helping them to resolve the ambivalence with which they approach treatment. (4,9) The principles of motivational interviewing are:

* Expressing empathy so that patients feel understood and accepted (4)

* Encouraging patients to recognize a personally meaningful discrepancy between their goals and their current state to motivate change (4)

* Exploring patient resistance to better understand the individual's point of view, personal struggles, and obstacles to adherence, and then using these perspectives as a resource for finding answers and solutions (4)

* Supporting patients' confidence in their ability to change (self-efficacy) (4)

Four interaction techniques, known by the mnemonic OARS, form the foundation of this patient-centered approach (Table 7). (4)

Psychoeducation is another strategy that specifically addresses misconceptions regarding bipolar disorder; it can be provided in a group setting or to patients and their partners or families. (10) Other efficacious approaches include cognitive-behavioral therapy, in which a patient's pattern of thoughts and feelings about medication and illness is systematically challenged to produce healthier behaviors and beliefs. (10)

Regardless of the strategy used to explore and address a patient's motivation, knowledge gaps, or cognitive patterns, the plan should be individualized in terms of its accessibility, affordability, and practicality to optimize its implementation. (8) Effective interventions also encompass family members, whenever possible, and encourage continual interaction between patients and health care professionals, with the goal of fostering an understanding of bipolar disorder and its treatment options by all involved in the care of individuals with the illness. (10)

LATUDA: A Treatment Option for Bipolar Depression

The efficacy of LATUDA was established in a 6-week monotherapy study and a 6-week adjunctive therapy study with lithium or valproate in adult patients with bipolar depression. The effectiveness of LATUDA has not been established for longer-term use (more than 6 weeks) or for the treatment of mania associated with bipolar disorder. (11)

The results of a phase 3, randomized, multicenter, double-blind, placebo-controlled clinical trial that examined the efficacy and safety of LATUDA monotherapy for patients with bipolar I depression were published in the February 2014 Issue of The American Journal of Psychiatry. (12) Adult patients (N=505) with major depressive episodes associated with bipolar I disorder, with or without rapid cycling and without psychotic features, were evaluated for eligibility. (12) All psychotropic medications were tapered off, and patients were randomly assigned to 1 of 3 treatment groups: flexibly dosed LATUDA 20-60 mg/day (N=166), flexibly dosed LATUDA 80-120 mg/day (N=169), or placebo (N=170). (12) LATUDA dosing adjustments were permitted for patients in both LATUDA groups to optimize efficacy and tolerability. (12) Study medication was taken once daily In the evening by mouth with a meal (eg, dinner) or within 30 minutes after eating. (12)

Short-term Efficacy

Figure 1 shows the Improvement in depressive symptoms for the LATUDA and placebo groups from baseline to Week 6 as measured using the Montgomery-Asberg Depression Rating Scale (MADRS) score, which was the study's primary efficacy endpoint. (12) The MADRS is a 10-Item, clinician-rated scale with scores ranging from 0 to 60. At Week 6, LATUDA 20-60 mg/day and 80-120 mg/day were associated with significantly greater improvement in MADRS score from baseline to the 6-week endpoint than placebo (-15.4 for both LATUDA treatment groups vs -10.7 for the placebo group; P < .001 for each LATUDA group vs placebo). (12) The higher dosage range (80-120 mg/day) did not provide additional efficacy, on average, compared with the lower dosage range (20-60 mg/day). (12)

Short-term Safety

Figure 2 shows the incidence of adverse reactions occurring in [greater than or equal to] 2% of patients in either LATUDA group and at greater incidence than placebo during acute therapy (up to 6 weeks in patients with bipolar depression). (11) Treatment was discontinued prematurely due to adverse events by 20 of 331 patients (6.0%) who received LATUDA 20-120 mg/day, and by 9 of 168 patients (5.4%) who received placebo. (11)

In the short-term study of LATUDA as monotherapy, the mean change in body weight from baseline to Week 6 was + 1.2 pounds for patients who received LATUDA 20-60 mg/day, 0.0 pounds for patients who received LATUDA 80-120 mg/day, and -0.1 pound for patients who received placebo. (11) Increase of body weight of at least 7.0% was noted for 2.4% of patients who received LATUDA versus 0.7% of patients who received placebo. (11) Changes in fasting glucose and lipids for the LATUDA and placebo groups are shown in Table 2. (11)

The median prolactin concentration increased by 1.7 ng/mL for the LATUDA 20-60 mg group, 3.5 ng/mL for the LATUDA 80-120 mg group, and 0.3 ng/mL for the placebo group. For male patients, the median change from baseline to Week 6 was +1.2 ng/mL, +1.9 ng/mL, and +0.4 ng/mL for the low-dose LATUDA, hlgh-dose LATUDA, and placebo groups, respectively; for female patients, the corresponding median changes from baseline were + 1.8 ng/mL, +5.3 ng/mL, and 0.0 ng/mL, respectively. (11)

Extrapyramldal symptoms (EPS) observed during the 6-week LATUDA monotherapy study included akathisia (noted for 8%, 11%, and 2% of patients in the LATUDA 20-60 mg, LATUDA 80-120 mg, and placebo groups, respectively), dystonia (0%, 2%, and 0%), parkinsonism (5%, 8%, and 2%), and restlessness (0%, 3%, and <1%). (11) EPS, akathisia, and dyskinesia were also examined using the Simpson-Angus Scale (SAS), the Barnes Akathisia Scale (BAS), and the Abnormal Involuntary Movement Scale (AIMS), respectively. (11) On the SAS, a shift from normal at baseline to an abnormal score at Week 6 (or at last observation carried forward for patients who discontinued prematurely) was noted for 3.7% of patients who received LATUDA 20-120 mg/day versus 1.9% of patients receiving placebo. On the BAS, worsening from baseline to endpoint was noted for 8.4% versus 5.6% of patients who received LATUDA or placebo, respectively, whereas on the AIMS, worsening from baseline was noted for 3.4% of patients who received LATUDA versus 1.2% of those receiving placebo. (11)

References

(1.) Montes JM, Maurino J, de Dios C, Medina E. Suboptimal treatment adherence in bipolar disorder: impact on clinical outcomes and functioning. Patient Prefer Adherence. 2013;7:89-94.

(2.) Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537.

(3.) Simon NM, Otto MW, Weiss RD, et al. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004;24(5):512-520.

(4.) Laakso LJ. Motivational interviewing: addressing ambivalence to improve medication adherence in patients with bipolar disorder. Issues Ment Health Nurs. 2012;33(1):8-14.

(5.) Levin JB, Krivenko A, Bukach A, Tatsuoka C, Cassidy KA, Sajatovic M. A reexamination of nonpsychiatric medication adherence in individuals with bipolar disorder and medical comorbidities [published online June 10, 2016]. J Nerv Ment Dis. 2016. doi: 10.1097/NMD.0000000000000544.

(6.) Maina G, Bechon E, Rigardetto S, Salvi V. General medical conditions are associated with delay to treatment in patients with bipolar disorder. Psychosomatics. 2013;54(5):437-442.

(7.) Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011 ;23(1):40-47.

(8.) Levin JB, Krivenko A, Howland M, Schlachet R, Sajatovic M. Medication adherence in patients with bipolar disorder: a comprehensive review. CNS Drugs. 2016;30(9):819-835.

(9.) McKenzie K, Chang YP The effect of nurse-led motivational interviewing on medication adherence in patients with bipolar disorder. Perspect Psychiatr Care. 2015;51 (1):36-44.

(10.) Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv. 2004;55(3):264-269.

(11.) LATUDA[R] [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2013.

(12.) Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160-168.

This newsletter series was developed and brought to you by Sunovion Pharmaceuticals Inc. It did not undergo peer review by CURRENT PSYCHIATRY. Newsletter content was developed in collaboration with the faculty.

Faculty

Vivien K. Burt, MD, PhD

Professor Emeritus of Psychiatry

Department of Psychiatry and Biobehavioral Sciences

David Geffen School of Medicine at University of California, Los Angeles

Co-Director

The Women's Life Center

Department of Psychiatry and

Biobehavioral Sciences

Resnick Neuropsychiatric Hospital at UCLA

Los Angeles, California

Catherine R. Judd, MS, PA-C, CAQ-Psychiatry, DFAAPA

Clinical Assistant Professor

Department of Physician Assistant Studies

University of Texas Southwestern Medical Center School of Health Professions

Physician Assistant

Mental Health and Behavioral Medicine

Parkland Health and Hospital System

Dallas, Texas

Mauricio Tohen, MD, DrPH, MBA

Professor and Chairman

Department of Psychiatry

The University of New Mexico

Albuquerque, New Mexico

DISCLOSURES

Dr. Burt serves or has served as a consultant and speaker for various pharmaceutical companies, including Sunovion, Ms. Judd and Dr. Tohen serve or have served as consultants, speakers, and researchers for various pharmaceutical companies, including Sunovion.

The clinical expert commentary reflects the view of an actual licensed clinician who has been engaged by Sunovion. The information contained herein is intended for general informational purposes only and is not a substitute for your professional medical advice and judgment.

This supplement is sponsored by

LATUDA. SUNOVION. and # are registered trademarks of Sumitomo Oainippon Pharma Co.. Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

[c] 2016 Sunovion Pharmaceuticals Inc.

All rights reserved. 11/16LAT1156-16

Watch a video about the impact of lifestyle factors on adherence and outcomes.

Visit www.CurrentPsychiatry.com/BipolarDepression.
TABLE 1. MOTIVATIONAL INTERVIEWING SKILLS AND EXAMPLES (4)

Skill                   Example Question(s) or Statement(s)

Open-ended questions    "Tell me about not taking your medication.
                        What is good about it? And what is the other
                        side? What worries you about not taking your
                        medication?"

Affirmations            "I understand that you didn't want to come
                        back to the hospital, but you did anyway. I
                        admire you for coming back to get help,
                        knowing that it wasn't easy for you."

Reflective listening    "You have recently lost a job, and that seems
                        to be very hard for you."

Summaries               "Let me stop us here and summarize some of the
                        things that we've just talked about. So you've
                        told me that you don't want to continue taking
                        your medication because you have gained weight
                        in the past. But at the same time, it sounds
                        like you have had trouble managing your
                        symptoms without your medication, which has
                        impacted your marriage, your work, and your
                        overall health. Did I miss anything? How do
                        you feel about all these things?" y

Laakso LJ. Motivational interviewing: addressing ambivalence to
improve medication adherence in patients with bipolar disorder. Issues
Merit Health Nurs. 2012;33(1):8-14. Reprinted by permission of Taylor
& Francis Ltd.

TABLE 2. CHANGE IN LABORATORY PARAMETERS FROM BASELINE TO WEEK 6
IN PATIENTS RANDOMIZED TO TREATMENT WITH LATUDA MONOTHERAPY OR
PLACEBO (11)

Parameter                     LATUDA 20-60 mg      LATUDA 80-120 mg

Glucose (mean)              -0.8 mg/dL (n=140)    +1.8 mg/dL (n=143)
Total cholesterol (mean)    +1.2 mg/dL (n=140)    -4.6 mg/dL (n=144)
Triglycerides (mean)        +5.6 mg/dL (n=140)    +0.4 mg/dL (n=144)

Parameter                         Placebo

Glucose (mean)              +1.8 mg/dL (n=148)
Total cholesterol (mean)    -3.2 mg/dL (n=147)
Triglycerides (mean)        +6.0 mg/dL (n=147)

FIGURE 1. PRIMARY EFFICACY ENDPOINT:
MADRS SCORE (12)

LS Mean Change From Baseline

Time (Weeks)

LATUDA 20-60 mg (n = 161)   -15.4 ***
LATUDA 80-120 mg (n = 162)  -15.4 ***
Placebo (n = 162)           -10.7

Baseline mean =

LATUDA 20-60 mg (n = 161)   30.3
LATUDA 80-120 mg (n = 162)  30.6
Placebo (n = 162)           30.5

* P<.05; ** P<.01; *** P<.001.

Abbreviations: LS, least squares; MADRS, Montgomery-Asberg

Depression Rating Scale.

MADRS scale range, 0-60.

Note: Table made from line graph.

FIGURE 2. ADVERSE REACTIONS IN [greater than or equal to] 2% OF
LATUDA-TREATED PATIENTS AND AT GREATER INCIDENCE THAN PLACEBO (11)

                  LATUDA      LATUDA       Placebo
                  20-60 mg    80-120 mg   (N = 164)
                  (N = 164)   (N = 167)

Nausea               10          17           8
Akathisia             8          11          12
Somnolence *          7          14           7
Dry Mouth             6           4           4
EPS ([dagger])        5           9           2
Diarrhea              5           3           2
Anxiety               4           5           1
Nasopharyngitis       4           4           1
Back Pain             3          <1          <1
Vomiting              2           6           2
UTI                   2           1          <1
Influenza            <1           2           1

Abbreviations: EPS, extrapyramidal symptoms; UTI, urinary tract
infection.

* Somnolence includes adverse event terms: hypersomnia,
hypersomnolence, sedation, and somnolence.

([double dagger]) EPS includes bradykinesia, cogwheel rigidity,
drooling, dystonia, extrapyramidal disorder, glabellar reflex
abnormal, hypokinesia, muscle rigidity, oculogyric crisis,
oromandibular dystonia, parkinsonism, psychomotor retardation,
tongue spasm, torticollis, tremor, and trismus.


AN EXPERT'S PERSPECTIVE

Commentary by Vivien K. Burt, MD, PhD

Among the challenges frequently faced by patients with bipolar disorder is adherence to treatment plans. As noted in this newsletter, a number of factors predict poor adherence, including a recent history of depression, current depressive symptoms (both severe and subsyndromal), and illicit substance use. In particular, I have found that bipolar depression, which is often so pervasive that it is difficult for patients to get out of bed, to leave home, or to see any hope for emerging from its debilitating effects, makes adherence more difficult.

My clinical experience underscores the effectiveness of emotionally connecting with patients and encouraging them to express their concerns about prescribed medications and other aspects of their treatment regimen. By resonating with patients' concerns and expressing a sincere appreciation for their real-life stresses, a continuum of trust is established that fosters adherence to treatment plans made in a multidisciplinary team setting. Empathizing with patients who struggle with bipolar disorder opens up avenues to explore the thoughts that have triggered those feelings. Once these thoughts have been expressed and shared with a caring and involved team of health care professionals, substantive discussions can be held to address and effectively treat symptoms, side effects, and other issues that hinder treatment adherence. Involving significant others and encouraging patient feedback can also support these efforts. Ultimately, I have found that an ongoing patient-provider dialogue helps improve psychiatric and medical outcomes in patients with bipolar disorder.

BRIEF SUMMARY OF LATUDA FULL PRESCRIBING INFORMATION

WARNINGS:

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS

* Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1)].

* LATUDA is not approved for use in patients with dementia-related psychosis [see Warnings and Precautions (5.1)].

* Antidepressants increased the risk of suicidal thoughts and behavior In children, adolescents, and young adults in short-term studies. These studies did not show an increase In the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.2)].

* In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE

1.1 Schizophrenia

LATUDA is indicated for the treatment of patients with schizophrenia.

The efficacy of LATUDA in schizophrenia was established in five 6-week controlled studies of adult patients with schizophrenia [see Clinical Studies (14.1)].

The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the Individual patient [see Dosage and Administration (2)].

1.2 Depressive Episodes Associated with Bipolar I Disorder

Monotherapy: LATUDA is indicated as monotherapy for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression). The efficacy of LATUDA was established in a 6-week monotherapy study in adult patients with bipolar depression [see Clinical Studies (14.2)].

Adjunctive Therapy with Lithium or Valproate: LATUDA is indicated as adjunctive therapy with either lithium or valproate for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression). The efficacy of LATUDA as adjunctive therapy was established in a 6-week study in adult patients with bipolar depression who were treated with lithium or valproate [see Clinical Studies (14.2)].

The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.2)].

The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established.

4 CONTRAINDICATIONS

* Known hypersensitivity to lurasidone HCI or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].

* Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].

* Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely In patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6- to 1.7-times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. LATUDA is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning]

5.2 Suicidal Thoughts and Behaviors In Adolescents and Young Adults

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment.

Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials In adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk of differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1.

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either Increases or decreases.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidal thoughts and behaviors, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for LATUDA should be written for the smallest quantity of capsules consistent with good patient management in order to reduce the risk of overdose.

5.3 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis

In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis [see also Boxed Warning and Warnings and Precautions (5.1)].

5.4 Neuroleptic Malignant Syndrome

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including LATUDA.

Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. If reintroduced, the patient should be carefully monitored, since recurrences of NMS have been reported.

5.5 Tardive Dyskinesia

Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become Irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment Is withdrawn. Antipsychotic treatment, Itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that spptomatic suppression has upon the long-term course of the syndrome Is unknown.

Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic Illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear In a patient on LATUDA, drug discontinuation should be considered. However, some patients may require treatment with LATUDA despite the presence of the syndrome.

5.6 Metabolic Changes

Atypical antipsychotic drugs have been associated with metabolic changes that may Increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemla, and body weight gain. While all of the drugs In the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperulvcemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotlcs. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities Is complicated by the possibility of an Increased background risk of diabetes mellitus In patients with schizophrenia and the Increasing incidence of diabetes mellitus In the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events Is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events In patients treated with the atypical antipsychotics. Because LATUDA was not marketed at the time these studies were performed, it is not known If LATUDA is associated with this Increased risk.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Schizophrenia

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 2.

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies). LATUDA was associated with a mean change in glucose of +1.8 mg/dL at week 24 (n=355), +0.8 mg/dL at week 36 (n=299) and +2.3 mg/dL at week 52 (n=307).

Bipolar Depression

Monotherapy

Data from the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study are presented In Table 3.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as monotherapy In the short-term study and continued In the longer-term study, had a mean change In glucose of +1.2 mg/dL at week 24 (n=129).

Adjunctive Therapy with Lithium or Valproate

Data from the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented In Table 4.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change In glucose of +1.7 mg/dL at week 24 (n=88). Dyslipidemia

Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics. Schizophrenia

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 5.

Bipolar Depression

Monotherapy

Data from the short-term, flexible-dosed. placebo-controlled, monotherapy bipolar depression study are presented In Table 6.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as monotherapy in the short-term and continued in the longer-term study had a mean change in total cholesterol and triglycerides of -0.5 (n=130) and -1.0 (n=130) mg/dL at week 24, respectively. Adjunctive Therapy with Lithium or Valproate

Data from the short-term, flexible-dosed, placebo-controlled, adjunctive therapy bipolar depression studies are presented in Table 7.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA, as adjunctive therapy with either lithium or valproate in the short-term study and continued In the longer-term study, had a mean change in total cholesterol and triglycerides of -0.9 (n=88) and 5.3 (n=88) mg/dL at week 24, respectively.

Weight Gain

Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Schizophrenia

Holed data from short-term, placebo-controlled schizophrenia studies are presented in Table 8. The mean weight gain was +0.43 kg for LATUDA-treated patients compared to -0.02 kg for placebo-treated patients. Change in weight from baseline for olanzapine was +4.15 kg and for quetiapine extended-release was +2.09 kg in Studies 3 and 5 [see Clinical Studies (14.1)], respectively. The proportion of patients with a [greater than or equal to] 7% increase In body weight (at Endpoint) was 4.8% for LATUDA-treated patients versus 3.3% for placebo-treated patients.

Bipolar Depression

Monotherapy

Data from the short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study are presented In Table 9. The mean weight gain was +0.29 kg for LATUDA-treated patients Compared to -0.04 kg for placebo-treated patients. The proportion of patients with a [greater than or equal to] 7% increase in body weight (at Endpoint) was 2.4% for LATUDA-treated patients versus 0.7% for placebo-treated patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as monotherapy In the short-term and continued In the longer-term study had a mean change In weight of -0.02 kg at week 24 (n=130).

Adjunctive Therapy with Lithium or Valproate

Data from the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented In Table 10. The mean weight gain was +0.11 kg for LATUDA-treated patients compared to +0.16 kg for placebo-treated patients. The proportion of patients with a [greater than or equal to] 7% increase in body weight (at Endpoint) was 3.1% ter LATUDA-treated patients versus 0.3% for placebo-treated patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA, as adjunctive therapy with either lithium or valproate in the short-term and continued In the longer-term study, had a mean change in weight of +1.28 kg at week 24 (n=86).

5.7 Hyperprolactinemia

As with other drugs that antagonize dopamine D receptors, LATUDA elevates prolactin levels.

Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis In both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and Impotence have been reported with prolactin-elevating compounds. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in both female and male patients [see Adverse Reactions (6)].

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs Is considered in a patient with previously detected breast cancer. As is common with compounds which Increase prolactin release, an Increase in mammary gland neoplasia was observed In a LATUDA carcinogenicity study conducted in rats and mice [see Nonclinical Toxicology (13)]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Schizophrenia

In short-term, placebo-controlled schizophrenia studies, the median change from baseline to endpoint in prolactin levels for LATUDA-treated patients was +0.4 ng/mL and was -1.9 ng/mL in the placebo-treated patients. The median change from baseline to endpoint for males was +0.5 ng/mL and for females was -0.2 ng/mL. Median changes for prolactin by dose are shown in Table 11.

The proportion of patients with prolactin elevations [greater than or equal to] 5x upper limit of normal (ULN) was 2.8% for LATUDA-treated patients versus 1.0% for placebo-treated patients. The proportion of female patients with prolactin elevations [greater than or equal to] 5x ULN was 5.7% for LATUDA-treated patients versus 2.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations [greater than or equal to] 5x ULN was 1.6% versus 0.6% for placebo-treated male patients.

In the uncontrolled longer-term schizophrenia studies (primarily open-label extension studies), LATUDA was associated with a median change in prolactin of -0.9 ng/mL at week 24 (n=357), -5.3ng/mL at week 36 (n=190) and -2.2 ng/mL at week 52 (n=307).

Bipolar Depression

Monotherapy

The median change from baseline to endpoint in prolactin levels, In the short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, was +1.7 ng/mL and +3.5 ng/mL with LATUDA 20 to 60 mg/day and 80 to 120 mg/day, respectively compared to +0.3 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +1.5 ng/mL and for females was +3.1 ng/mL. Median changes for prolactin by dose range are shown in Table 12.

The proportion of patients with prolactin elevations [greater than or equal to] 5x upper limit of normal (ULN) was 0.4% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations [greater than or equal to] 5x ULN was 0.6% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations [greater than or equal to] 5x ULN was 0% versus 0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA as monotherapy in the short-term and continued in the longer-term study, had a median change In prolactin of -1.15 ng/mL at week 24 (n=130).

Adjunctive Therapy with Lithium or Valproate

The median change from baseline to endpoint in prolactin levels, In the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies was +2.8 ng/mL with LATUDA 20 to 120 mg/day compared to 0.0 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +2.4 ng/mL and for females was +3.2 ng/mL. Median changes for prolactin across the dose range are shown in Table 13.

The proportion of patients with prolactin elevations [greater than or equal to] 5x upper limit of normal (ULN) was 0.0% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations [greater than or equal to] 5x ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations [greater than or equal to] 5x ULN was 0% versus 0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA. as adjunctive therapy with either lithium or valproate, in the short-term and continued in the longer-term study, had a median change in prolactin of -2.9 ng/mL at week 24 (n=88).

5.8 Leukopenia, Neutropenia and Agranulocytosis

Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and LATUDA should be discontinued at the first sign of decline in WBC, in the absence of other causative factors.

Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count < 1000/[mm.sup.3]) should discontinue LATUDA and have their WBC followed until recovery.

5.9 Orthostatic Hypotension and Syncope

LATUDA may cause orthostatic hypotension and syncope, perhaps due to its [alpha]1-adrenergic receptor antagonism. Associated adverse reactions can include dizziness, lightheadedness, tachycardia, and bradycardia. Generally, these risks are greatest at the beginning of treatment and during dose escalation. Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naive. In such patients, consider using a lower starting dose and slower titration, and monitor orthostatic vital signs.

Orthostatic hypotension, as assessed by vital sign measurement, was defined by the following vital sign changes: [greater than or equal to] 20 mm Hg decrease in systolic blood pressure and [greater than or equal to] 10 bpm increase in pulse from sitting to standing or supine to standing position.

Schizophrenia

The incidence of orthostatic hypotension and syncope reported as adverse events from short-term, placebo-controlled schizophrenia studies was (LATUDA incidence, placebo incidence): orthostatic hypotension [0.3% (5/1508), 0.1% (1/708)] and syncope [0.1% (2/1508), 0% (0/708)].

In short-term schizophrenia clinical studies, orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.8% with LATUDA 40 mg, 2.1% with LATUDA 80 mg, 1.7% with LATUDA 120 mg and 0.8% with LATUDA 160 mg compared to 0.7% with placebo.

Bipolar Depression

Monotherapy

In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, there were no reported adverse events of orthostatic hypotension and syncope.

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.6% with LATUDA 20 to 60 mg and 0.6% with LATUDA 80 to 120 mg compared to 0% with placebo. Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression therapy studies, there were no reported adverse events of orthostatic hypotension and syncope. Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with LATUDA 20 to 120 mg compared to 0.9% with placebo.

5.10 Seizures

As with other antipsychotic drugs, LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Schizophrenia

In short-term, placebo-controlled schizophrenia studies, seizures/convulsions occurred in 0.1% (2/1508) of patients treated with LATUDA compared to 0.1% (1/708) placebo-treated patients.

Bipolar Depression

Monotherapy

In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, no patient experienced seizures/convulsions.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, no patient experienced seizures/convulsions.

5.11 Potential for Cognitive and Motor Impairment

LATUDA, like other antipsychotics, has the potential to impair judgment, thinking or motor skills. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

In clinical studies with LATUDA, somnolence included: hypersomnia, hypersomnolence, sedation and somnolence.

Schizophrenia

In short-term, placebo-controlled schizophrenia studies, somnolence was reported by 17.0% (256/1508) of patients treated with LATUDA (15.5% LATUDA 20 mg, 15.6% LATUDA 40 mg, 15.2% LATUDA 80 mg, 26.5% LATUDA 120 mg and 8.3% LATUDA 160 mg/day) compared to 7.1% (50/708) of placebo patients.

Bipolar Depression

Monotherapy

In the short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, somnolence was reported by 7.3% (12/164) and 13.8% (23/167) with LATUDA 20 to 60 mg and 80 to 120 mg, respectively compared to 6.5% (11/168) of placebo patients.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies, somnolence was reported by 11.4% (41/360) of patients treated with LATUDA 20-120 mg compared to 5.1% (17/334) of placebo patients.

5.12 Body Temperature Dysregulation

Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration [see Patient Counseling Information (17.9)].

5.13 Suicide

The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Schizophrenia

In short-term, placebo-controlled schizophrenia studies, the incidence of treatment-emergent suicidal ideation was 0.4% (6/1508) for LATUDA-treated patients compared to 0.8% (6/708) on placebo. No suicide attempts or completed suicides were reported in these studies.

Bipolar Depression

Monotherapy

In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the incidence of treatment-emergent suicidal ideation was 0.0% (0/331) with LATUDA-treated patients compared to 0.0% (0/168) with placebo-treated patients. No suicide attempts or completed suicides were reported in this study.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, the incidence of treatment-emergent suicidal ideation was 1.1% (4/360) for LATUDA-treated patients compared to 0.3% (1/334) on placebo. No suicide attempts or completed suicides were reported in these studies.

5.14 Activation of Mania/Hypomania

Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. Monitor patients for the emergence of such episodes.

In the bipolar depression monotherapy and adjunctive therapy (with lithium or valproate) studies, less than 1% of subjects in the LATUDA and placebo groups developed manic or hypomanic episodes.

5.15 Dysphagia

Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

5.16 Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

* Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions (5.1)]

* Suicidal Thoughts and Behaviors [see Boxed Warning and Warnings and Precautions (5.2)]

* Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-related Psychosis [see Warnings and Precautions (5.23)]

* Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.4)]

* Tardive Dyskinesia [see Warnings and Precautions (5.5)]

* Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.6)]

* Hyperprolactinemia [see Warnings and Precautions (5.7)]

* Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.8)]

* Orthostatic Hypotension and Syncope [see Warnings and Precautions (5.9)]

* Seizures [see Warnings and Precautions (5.10)]

* Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.11)]

* Body Temperature Dysregulation [see Warnings and Precautions (5.12)]

* Suicide [see Warnings and Precautions (5.13)]

* Activation of Mania/Hypomania [see Warnings and Precautions (5.14)]

* Dysphagia [see Warnings and Precautions (5.15)]

* Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies [see Warnings and Precautions (5.16)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The information below is derived from an integrated clinical study database for LATUDA consisting of 3799 patients exposed to one or more doses of LATUDA for the treatment of schizophrenia and bipolar depression in placebo-controlled studies. This experience corresponds with a total experience of 1250.9 patient-years. A total of 1106 LATUDA-treated patients had at least 24 weeks and 371 LATUDA-treated patients had at least 52 weeks of exposure.

Adverse events during exposure to study treatment were obtained by general inquiry and voluntarily reported adverse experiences, as well as results from physical examinations, vital signs, ECGs, weights and laboratory investigations. Adverse experiences were recorded by clinical investigators using their own terminology. In order to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

Schizophrenia

The following findings are based on the short-term, placebo-controlled premarketing studies for schizophrenia in which LATUDA was administered at daily doses ranging from 20 to 160 mg (n=1508).

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence [greater than or equal to] 5% and at least twice the rate of placebo) in patients treated with LATUDA were somnolence, akathisia. extrapyramidal symptoms, and nausea.

Adverse Reactions Associated with Discontinuation of Treatment A total of 9.5% (143/1508) LATUDA-treated patients and 9.3% (66/708) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.

Adverse Reactions Occurring at an Incidence of 2% or Mote in LATUDA-Treated Patients: Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with schizophrenia) are shown in Table 14.

Dose-Related Adverse Reactions in the Schizophrenia Studies

Akathisia and extrapyramidal symptoms were dose-related. The frequency of akathisia increased with dose up to 120 mg/day (5,6% for LATUDA 20 mg, 10.7% for LATUDA 40 mg, 12.3% for LATUDA 80 mg, and 22.0%for LATUDA 120 mg). Akathisia was reported by 7.4% (9/121) of patients receiving 160 mg/day. Akathisia occurred in 3.0% of subjects receiving placebo. The frequency of extrapyramidal symptoms increased with dose up to 120 mg/day (5.6% for LATUDA 20 mg, 11.5% for LATUDA 40 mg, 11.9% for LATUDA 80 mg, and 22.0% for LATUDA 120 mg).

Bipolar Depression (Monotherapy)

The following findings are based on the short-term, placebo-controlled premarketing study for bipolar depression in which LATUDA was administered at daily doses ranging from 20 to 120 mg (n=331).

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence [greater than or equal to] 5%, in either dose group, and at least twice the rate of placebo) in patients treated with LATUDA were akathisia, extrapyramidal symptoms, somnolence, nausea, vomiting, diarrhea, and anxiety. Adverse Reactions Associated with Discontinuation of Treatment: A total of 6.0% (20/331) LATUDA-treated patients and 5.4% (9/168) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.

Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients: Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with bipolar depression) are shown in Table 15,

Dose-Related Adverse Reactions in the Monotherapy Study.

In the short-term, placebo-controlled study (Involving lower and higher LATUDA dose ranges) [see Clinical Studies (14.2)] the adverse reactions that occurred with a greater than 5% incidence in the patients treated with LATUDA in any dose group and greater than placebo in both groups were nausea (10.4%, 17.4%), somnolence (7.3%, 13.8%), akathisia (7.9%, 10.8%), and extrapyramidal symptoms (4.9%, 9.0%) for LATUDA 20 to 60 mg/day and LATUDA 80 to 120 mg/day, respectively.

Bipolar Depression

Adjunctive Therapy with Lithium or Valproate

The following findings are based on two short-term, placebo-controlled premarketing studies for bipolar depression in which LATUDA was administered at daily doses ranging from 20 to 120 mg as adjunctive therapy with lithium or valproate (n=360).

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence [greater than or equal to] 5% and at least twice the rate of placebo) in subjects treated with LATUDA were akathisia and somnolence. Adverse Reactions Associated with Discontinuation of Treatment A total of 5.8% (21/360) LATUDA-treated patients and 4.8% (16/334) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.

Adverse Reactions Occurring at an incidence of 2% or More in LATUDA-Treated Patients: Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with bipolar depression) are shown in Table 16.

Extrapyramidal Symptoms

Schizophrenia

In the short-term, placebo-controlled schizophrenia studies, for LATUDA-treated patients, the Incidence of reported events related to extrapyramidal symptoms (EPS), excluding akathisia and restlessness, was 13.5% versus 5,8% for placebo-treated patients. The incidence of akathisia for LATUDA-treated patients was 12,9% versus 3.0% for placebo-treated patients. Incidence of EPS by dose is provided in Table 17.

Bipolar Depression

Monotherapy

In the short-term, placebo-controlled monotherapy bipolar depression study, for LATUDA-treated patients, the incidence of reported events related to EPS, excluding akathisia and restlessness was 6.9% versus 2.4% for placebo-treated patients. The incidence of akathisia for LATUDA-treated patients was 9.4% versus 2.4% for placebo-treated patients. Incidence of EPS by dose groups is provided in Table 18.

Adjunctive Therapy with Lithium or Valproate

In the short-term, placebo-controlled adjunctive therapy bipolar depression studies, for LATUDA-treated patients, the incidence of EPS, excluding akathisia and restlessness, was 13.9% versus 8.7% for placebo. The incidence of akathisia for LATUDA-treated patients was 10.8% versus 4.8% for placebo-treated patients. Incidence of EPS is provided In Table 19.

In the short-term, placebo-controlled schizophrenia and bipolar depression studies, data was objectively collected on the Simpson Angus Rating Scale (SAS) for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (BAS) for akathisia and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesias.

Schizophrenia

The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients, with the exception of the Barnes Akathisia Scale global score (LATUDA, 0.1; placebo, 0.0). The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 14.4%; placebo, 7.1%), the SAS (LATUDA, 5.0%; placebo, 2.3%) and the AIMS (LATUDA, 7.4%; placebo, 5.8%).

Bipolar Depression

Monotherapy

The mean change from baseline for LATUDA-treated patients for the SAS. BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater In LATUDA-treated patients versus placebo for the BAS (LATUDA, 8.4%; placebo, 5.6%), the SAS (LATUDA, 3.7%; placebo, 1.9%) and the AIMS (LATUDA, 3.4%; placebo, 1.2%).

Adjunctive Therapy with Lithium or Valproate

The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 8.7%; placebo, 2.1%), the SAS (LATUDA, 2.8%; placebo, 2.1%) and the AIMS (LATUDA, 2.8%; placebo, 0.6%).

Dystonia

Class Effect Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur In susceptible individuals during the first few days of treatment. Dystonlc symptoms Include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia Is observed in males and younger age groups.

Schizophrenia

In the short-term, placebo-controlled schizophrenia clinical studies, dystonia occurred in 4.2% of LATUDA-treated subjects (0.0% LATUDA 20 mg, 3.5% LATUDA 40 mg. 4.5% LATUDA 80 mg, 6.5% LATUDA 120 mg and 2.5% LATUDA 160 mg) compared to 0.8% of subjects receiving placebo. Seven subjects (0.5%, 7/1508) discontinued clinical trials due to dystonic events - four were receiving LATUDA 80 mg/day and three were receiving LATUDA 120 mg/day.

Bipolar Depression

Monotherapy

In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, dystonia occurred in 0.9% of LATUDA-treated subjects (0.0% and 1.8% for LATUDA 20 to 60 mg/day and LATUDA 80 to 120 mg/day, respectively) compared to 0.0% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, dystonia occurred In 1.1% of LATUDA-treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

Other Adverse Reactions Observed During the Premarketing Evaluation of LATUDA

Following is a list of adverse reactions reported by patients treated with LATUDA at multiple doses of [greater than or equal to] 20 mg once daily within the premarketing database of 2905 patients with schizophrenia. The reactions listed are those that could be of clinical Importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions listed in Table 14 or those that appear elsewhere in the LATUDA label are not included. Although the reactions reported occurred during treatment with LATUDA, they were not necessarily caused by It.

Reactions are further categorized by organ class and listed In order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled studies appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring In fewer than 1/1000 patients (rare).

Blood and Lymphatic System Disorders: Infrequent: anemia

Cardiac Disorders: Frequent: tachycardia: Infrequent: AV block 1st degree, angina pectoris, bradycardia

Ear and Labyrinth Disorders: Infrequent: vertigo

Eye Disorders: Frequent: blurred vision

Gastrointestinal Disorders: Frequent: abdominal pain, diarrhea: Infrequent gastritis

General Disorders and Administrative Site Conditions: Rare: sudden death

Investigations: Frequent: CPK increased

Metabolism and Nutritional System Disorders: Frequent: decreased appetite

Musculoskeletal and Connective Tissue Disorders: Rare: rhabdomyolysis

Nervous System Disorders: Infrequent: cerebrovascular accident, dysarthria

Psychiatric Disorders: Infrequent: abnormal dreams, panic attack, sleep disorder

Renal and Urinary Disorders: Infrequent dysuria: Rare: renal failure

Reproductive System and Breast Disorders: Infrequent amenorrhea, dysmenorrhea: Rare: breast enlargement, breast pain, galactorrhea, erectile dysfunction

Skin and Subcutaneous Tissue Disorders: Frequent rash, pmritus: Rare: angioedema

Vascular Disorders: Frequent hypertension

Clinical Laboratory Changes

Schizophrenia

Serum Creatinine: In short-term, placebo-controlled trials, the mean change from Baseline in serum creatinine was +0.05 mg/dL for LATUDA-treated patients compared to +0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 3.0% (43/1453) of LATUDA-treated patients and 1.6% (11/681) on placebo. The threshold for high creatinine value varied from > 0.79 to > 1.3 mg/dL based on the centralized laboratory definition for each study (Table 20).

Serum Creatinine: In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the mean change from Baseline in serum creatinine was +0.01 mg/dL for LATUDA-treated patients compared to -0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 2.8% (9/322) of LATUDA-treated patients and 0.6% (1/162) on placebo (Table 21).

Adjunctive Therapy with Lithium or Valproate

Serum Creatinine: In short-term, placebo-controlled premarketing adjunctive studies for bipolar depression, the mean change from Baseline in serum creatinine was +0.04 mg/dL for LATUDA-treated patients compared to -0.01 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 4.3% (15/360) of LATUDA-treated patients and 1.6% (5/334) on placebo (Table 22).

7 DRUG INTERACTIONS

7.1 Potential for Other Drugs to Affect L ATUDA

LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CVP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate Inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA Is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)].

Lithium: It is not necessary to adjust the LATUDA dose when used concomitantly with lithium (Figure 1).

Valproate: It is not necessary to adjust the LATUDA dose when used concomitantly with valproate. A dedicated drug-drug interaction study has not been conducted with valproate and LATUDA. Based on pharmacokinetic data from the bipolar depression studies valproate levels were not affected by lurasidone, and lurasidone concentrations were not affected by valproate.

Grapefruit: Grapefruit and grapefruit juice should be avoided in patients taking LATUDA, since these may inhibit CYP3A4 and alter LATUDA concentrations [see Dosage and Administration (2.5)].

7.2 Potential for LATUDA to Affect Other Drugs

No adjustment is needed for lithium, substrates of P-gp, CYP3A4 (Figure 2) or valproate when coadministered with LATUDA.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B

Risk Summary

There are no adequate and well controlled studies of LATUDA use in pregnant women. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while In some cases symptoms have been self-limited, In other cases neonates have required Intensive care unit support and prolonged hospitalization.

LATUDA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Human Data

Safe use of LATUDA during pregnancy or lactation has not been established; therefore, use of LATUDA in pregnancy, in nursing mothers, or in women of childbearing potential requires that the benefits of treatment be weighed against the possible risks to mother and child.

Animal Data

No adverse developmental effects were observed in a study in which pregnant rats were given lurasidone during the period of organogenesis and continuing through weaning at doses up to 10 mg/kg/day, which is approximately half of the maximum recommended human dose (MRHD) of 160 mg/day, based on mg/[m.sup.2] body surface area.

No teratogenic effects were seen in studies in which pregnant rats and rabbits were given lurasidone during the period of organogenesis at doses up to 25 and 50 mg/kg/day, respectively. These doses are 1.5- and 6-times, in rats and rabbits, respectively, the MRHD of 160 mg/day based on mg/[m.sup.2] body surface area.

8.3 Nursing Mothers

LATUDA was excreted in milk of rats during lactation. It is not known whether LATUDA or its metabolites are excreted in human milk. Because of the potential for serious adverse reactions in nursing Infants, a decision should be made whether to discontinue nursing or to discontinue the drug, considering the risk of drug discontinuation to the mother.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

Clinical studies with LATUDA did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients. In elderly patients with psychosis (65 to 85), LATUDA concentrations (20 mg/day) were similar to those In young subjects. It is unknown whether dose adjustment is necessary on the basis of age alone.

Elderly patients with dementia-related psychosis treated with LATUDA are at an Increased risk of death compared to placebo. LATUDA is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning]

8.6 Other Patient Factors

The effect of intrinsic patient factors on the pharmacokinetics of LATUDA is presented in Figure 3.

10 OVERDOSAGE

10.1 Human Experience

In premarketing clinical studies, accidental or intentional overdosage of LATUDA was identified in one patient who ingested an estimated 560 mg of LATUDA. This patient recovered without sequelae. This patient resumed LATUDA treatment for an additional two months.

10.2 Management of Overdosage

Consult a Certified Poison Control Center for up-to-date guidance and advice. There is no specific antidote to LATUDA. therefore, appropriate supportive measures should be Instituted and close medical supervision and monitoring should continue until the patient recovers. Consider the possibility of multiple-drug overdose.

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy Is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of LATUDA. Similarly, the alpha-blocking properties of bretylium might be additive to those of LATUDA, resulting in problematic hypotension.

Hypotension and circulatory collapse should be treated with appropriate measures. Epinephrine and dopamine should not be used, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension In the setting of LATUDA-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medication should be administered.

Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.

The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

SUNOVION

Manufactured for:

Sunovion Pharmaceuticals Inc. Marlborough, MA 01752 USA

For Customer Service, call 1-888-394-7377.

For Medical Information, call 1-800-739-0565.

To report suspected adverse reactions, call 1-877-737-7226.

Revised: July 2013 901456R10
Table 1

Age Range             Drug-Placebo Difference in Number of
                     Cases of Suicidality per 1000 Patients
                                    Treated

                         Increases Compared to Placebo

<18                           14 additional cases

18-24                          5 additional cases

                         Decreases Compared to Placebo

25-64                             1 fewer case

[greater than or                 6 fewer cases
equal to] 65

Table 2: Change in Fasting Glucose in Schizophrenia Studies

                                LATUDA

                   Placebo     20 mg/day    40 mg/day

Mean Change from Baseline (mg/dL)

                    n=680         n=71        n=478

Serum Glucose        -0.0         -0.6         +2.6

Proportion of Patients with Shifts to [greater than or equal to] 126
mg/dL

Serum Glucose        8.3%        11.7%        12.7%
([greater than     (52/628)      (7/60)      (57/449)
or equal to] 126
mg/dL)

                                 LATUDA

                  80 mg/day    120 mg/day   160 mg/day

Mean Change from Baseline (mg/dL)

                    n=508        n=283        n=113

Serum Glucose        -0.4         +2.5         +2.5

Proportion of Patients with Shifts to [greater than or equal to] 126
mg/dL

Serum Glucose        6.8%        10.0%         5.6%
([greater than     (32/472)     (26/260)     (6/108)
or equal to] 126
mg/dL)

Table 3: Change in Fasting Glucose in the Monotherapy Bipolar
Depression Study

                                          LATUDA

                   Placebo    20 to 60 mg/day   80 to 120 mg/day
                    n=148          n=140             n=143

Mean Change from Baseline (mg/dL)

Serum Glucose        +1.8          -0.8               +1.8

Proportion of Patients with Shifts to
[greater than or equal to] 126 mg/dL

Serum Glucose        4.3%          2.2%               6.4%
([greater than     (6/141)        (3/138)           (9/141)
or equal to] 126
mg/dL)

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day,
LATUDA 80 to 120 mg/day. or placebo

Table 4: Change in Fasting Glucose In the Adjunctive Therapy Bipolar
Depression Studies

                                    LATUDA

                   Placebo     20 to 120 mg/day

Mean Change from Baseline (mg/dL)

                    n=302            n=319

Serum Glucose        -0.9            +1.2

Proportion of Patients with Shifts to [greater than or equal to]
126 mg/dL

Serum Glucose        1.0%            1.3%
([greater than     (3/290)          (4/316)
or equal to]
126 mg/dL)

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day
or placebo as adjunctive therapy with lithium or valproate.

Table 5: Change in Fasting Lipids in Schizophrenia Studies

                                           LATUDA

                      Placebo      20 mg/day   40 mg/day

Mean Change from Baseline (mg/dL)

                       n=660         n=71        n=466

Total Cholesterol       -5.8         -12.3       -5.7

Triglycerides          -13.4         -29.1       -5.1

Proportion of Patients with Shifts

Total Cholesterol       5.3%         13.8%       6.2%
([greater than        (30/571)      (8/58)     (25/402)
or equal to] 240
mg/dL)

Triglycerides          10.1%         14.3%         10.8%
([greater than        (53/526)      (7/49)       (41/379)
or equal to]
200 mg/dL)

                                     LATUDA

                      80 mg/day    120 mg/day    160 mg/day

Mean Change from Baseline (mg/dL)

                        n=499         n=268         n=115

Total Cholesterol       -6.2          -3.8          -6.9

Triglycerides           -13.0         -3.1          -10.6

Proportion of Patients with Shifts

Total Cholesterol       5.3%          3.8%          4.0%
([greater than        (23/434)       (9/238)       (4/101)
or equal to]
240 mg/dL)

Triglycerides           6.3%          10.5%         7.0%
([greater than        (25/400)      (22/209)       (7/100)
or equal to]
200 mg/dL)

In the uncontrolled, longer/term schizophrenia studies (primarily
open/label extension studies), LATUDA was associated with a mean
change In total cholesterol and triglycerides of -3.8 (n=356) and
-15.1 (n=357) mg/dL at week 24, -3.1 (n=303) and -4.8 (n=303) mg/dL
at week 36 and -2.5 (n=307) and -6.9 (n=307) mg/dL at week 52,
respectively.

Table 6: Change in Fasting Lipids in the Monotherapy Bipolar
Depression Study

                                             LATUDA

                     Placebo    20 to 60 mg/day   80 to 120 mg/day

Mean Change from Baseline (mg/dL)

                      n=147          n=140             n=144

Total cholesterol      -3.2          +1.2               -4.6

Triglycerides          +6.0          +5.6               +0.4

Proportion of Patients with Shifts

Total cholesterol      4.2%          4.4%               4.4%
([greater than       (5/118)        (5/113)           (5/114)
or equal to] 240
mg/dL)

Triglycerides          4.8%          10.1%              9.8%
([greater than       (6/126)       (12/119)           (12/122)
or equal to] 200
mg/dL)

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day,
LATUDA 80 to 120 mg/day, or placebo

Table 7: Change in Fasting Lipids in the Adjunctive Therapy Bipolar
Depression Studies

                                                         LATUDA

                                         Placebo     20 to 120mg/day

Mean Change from Baseline mg/dL)

                                          n=303           n=321

Total cholesterol                          -2.9           -3.1

Triglycerides                              -4.6           +4.6

Proportion of Patients with Shifts

Total cholesterol                          5.7%           5.4%
([greater than or equal to] 240 mg/dL)   (15/263)       (15/276)

Triglycerides                              8.6%           10.8%
([greater than or equal to] 200 mg/dL)   (21/243)       (28/260)

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day
or placebo as adjunctive therapy with lithium or valproate.

Table 8: Mean Change in Weight (kg) from Baseline in Schizophrenia
Studies

                                      LATUDA

                 Placebo     20 mg/day    40 mg/day
                 (n=696)       (n=71)      (n=484)

All Patients      -0.02        -0.15        +0.22

                               LATUDA

                80 mg/day    120 mg/day   160 mg/day
                 (n=526)      (n=291)      (n=114)

All Patients      +0.54        +0.68        +0.60

In the uncontrolled, longer-term schizophrenia studies (primarily
open-label extension studies), LATUDA was associated with a mean
change in weight of -0.69 kg at week 24 (n=755), -0.59 kg at week 36
(n=443) and -0.73 kg at week 52 (n=377).

Table 9: Mean Change in Weight (kg) from Baseline in the
Monotherapy Bipolar Depression Study

                                         LATUDA

                Placebo    20 to 60 mg/day   80 to 120 mg/day
                (n=151)        (n=143)           (n=147)

All Patients     -0.04          +0.56             +0.02

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day,
LATUDA 80 to 120 mg/day, or placebo

Table 10: Mean Change in Weight (kg) from Baseline in the Adjunctive
Therapy Bipolar Depression Studies

                                LATUDA

                Placebo    20 to 120 mg/day
                (n=307)         (n=327)

All Patients     +0.16           +0.11

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day
or placebo as adjunctive therapy with lithium or valproate.

Table 11: Median Change in Prolactin (ng/mL) from Baseline in
Schizophrenia Studies

                                            LATUDA

                   Placebo        20 mg/day       40 mg/day

All Patients    -1.9 (n=672)     -1.1 (n=70)    -1.4 (n=476)
Females         -5.1 (n=200)     -0.7 (n=19)    -4.0 (n=149)
Males           -1.3 (n=472)     -1.2 07=51)    -0.7 (n=327)

                                    LATUDA

                  80 mg/day      120 mg/day      160 mg/day

All Patients    -0.2 (n=495)    +3.3 (n=284)    +3.3 (n=115)
Females         -0.2 (n=150)     +6.7 01=70)     +7.1 (n=36)
Males           -0.2 (n=345)    +3.1 (n=214)     +2.4 (n=79)

Table 12: Median Change in Prolactin (ng/mL) from Baseline in
the Monotherapy Bipolar Depression Study

                                        LATUDA

                Placebo    20 to 60 mg/day   80 to 120 mg/day

All Patients      +0.3          +1.7               +3.5
                (n=147)        (n=140)           (n=144)

Females           0.0           +1.8               +5.3
                 (n=82)        (n=78)             (n=88)

Males             +0.4          +1.2               +1.9
                 (n=65)        (n=62)             (n=56)

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day,
LATUDA 80 to 120 mg/day, or placebo

Table 13: Median Change in Prolactin (ng/mL) from Baseline in the
Adjunctive Therapy Bipolar Depression Studies

                                LATUDA

                Placebo    20 to 120mg/day

All Patients      0.0            +2.8
                (n=301)        (n=321)

Females           +0.4           +3.2
                (o=156)        (n=162)

Males             -0.1           +2.4
                (n=145)        (n=159)

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or
placebo as adjunctive therapy with lithium or valproate.

Table 14: Adverse Reactions in 2% or More of LATUDA-Treated Patients
and That Occurred at Greater Incidence than In the Placebo-Treated
Patients in Short-term Schizophrenia Studies

                      Percentage of Patients Reporting Reaction

                                                LATUDA

Body System or        Placebo    20 mg/day    40 mg/day    80 mg/day
Organ Class           (N=708)      (N=71)      (N=487)      (N=538)
                        (%)         (%)          (%)          (%)

Gastrointestinal Disorders
  Nausea                 5           11           10           9
  Vomiting               6           7            6            9
  Dyspepsia              5           11           6            5
  Salivary               <1          1            1            2
    Hypersecretion

Musculoskeletal and Connective Tissue Disorders
  Back Pain              2           0            4            3

Nervous System Disorders
  Somnolence *           7           15           16           15
  Akathisia              3           6            11           12
  Extrapyramidal         6           6            11           12
    Disorder **
  Dizziness              2           6            4            4

Psychiatric Disorders
  Insomnia               8           8            10           11
  Agitation              4           10           7            3
  Anxiety                4           3            6            4
                         1           1            3            1

                      Percentage of Patients Reporting Reaction

                                      LATUDA

Body System or        120 mg/day    160 mg/day     All LATUDA
Organ Class             (N=291)       (N=121)       (N=1508)
                          (%)           (%)           (%)

Gastrointestinal Disorders
  Nausea                  13             7             10
  Vomiting                 9             7             8
  Dyspepsia                8             6             6
  Salivary                 4             2             2
    Hypersecretion

Musculoskeletal and Connective Tissue Disorders
  Back Pain                4             0             3

Nervous System Disorders
  Somnolence *            26             8             17
  Akathisia               22             7             13
  Extrapyramidal          22            13             14
    Disorder **
  Dizziness                5             6             4

Psychiatric Disorders
  Insomnia                 9             7             10
  Agitation                6             5             5
  Anxiety                  7             3             5
                           3             2             2

Note: Figures rounded to the nearest integer

* Somnolence includes adverse event terms: hypersomnia,
hypersomnolence, sedation, and somnolence

** Extrapyramidal symptoms includes adverse event terms: bradykinesia,
cogwheel rigidity, drooling, dystonia, extrapyramidal disorder,
hypokinesia, muscle rigidity, oculogyric crisis, oromandibular
dystonia, parkinsonism, psychomotor retardation, tongue spasm,
torticollis, tremor, and trismus

Table 15: Adverse Reactions In 2% or More of LATUDA-Treated Patients
and That Occurred at Greater Incidence than in the Placebo-Treated
Patients in a Short-term Monotherapy Bipolar Depression Study

                              Percentage of Patients Reporting Reaction

                                          LATUDA     LATUDA      All
Body System or Organ Class    Placebo     20-60      80-120    LATUDA
Dictionary-derived Term       (N=168)     mg/day     mg/day    (N=331)
                                (%)      (N=164)    (N=167)      (%)
                                           (%)        (%)

Gastrointestinal Disorders
  Nausea                         8          10         17        14
  Dry Mouth                      4          6          4          5
  Vomiting                       2          2          6          4
  Diarrhea                       2          5          3          4
Infections and Infestations
  Nasopharyngitis                1          4          4          4
  Influenza                      1          <1         2          2
  Urinary Tract Infection        <1         2          1          2
Musculoskeletal and Connective Tissue Disorders
  Back Pain                      <1         3          <1         2
Nervous System Disorders
  Extrapyramidal Symptoms *      2          5          9          7
  Akathisia                      2          8          11         9
  Somnolence **                  7          7          14        11
Psychiatric Disorders
  Anxiety                        1          4          5          4

Note: Figures rounded to the nearest integer

* Extrapyramidal symptoms includes adverse event terms: bradykinesia,
cogwheel rigidity, drooling, dystonia, extrapyramidal disorder,
glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric
crisis, oromandibular dystonia, parkinsonism, psychomotor retardation,
tongue spasm, torticollis, tremor, and trismus

** Somnolence includes adverse event terms: hypersomnia,
hypersomnolence, sedation, and somnolence

Table 16: Adverse Reactions in 2% or More of LATUDA-Treated Patients
and That Occurred at Greater Incidence than in the Placebo-Treated
Patients in the Short-term Adjunctive Therapy Bipolar Depression
Studies

                                        Percentage of Patients
                                          Reporting Reaction

Body System or Organ Class            Placebo          LATUDA
Dictionary-derived Term             (N=334) (%)   20 to 120 mg/day
                                                    (N=360) (%)

Gastrointestinal Disorders
  Nausea                                 10               14
  Vomiting                               1                4
General Disorders
  Fatigue                                1                3
Infections and Infestations
  Nasopharyngitis                        2                4
Investigations
  Weight Increased                       <1               3
Metabolism and Nutrition Disorder
  Increased Appetite                     1                3
Nervous System Disorders
  Extrapyramidal Symptoms *              9                14
  Somnolence **                          5                11
  Akathisia                              5                11
Psychiatric Disorders
  Restlessness                           <1               4

Note: Figures rounded to the nearest integer

* Extrapyramidal symptoms includes adverse event terms: bradykinesia,
cogwheel rigidity, drooling, dystonia, extrapyramidal disorder,
glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric
crisis, oromandibular dystonia, parkinsonism, psychomotor retardation,
tongue spasm, torticollis, tremor, and trismus

** Somnolence includes adverse event terms: hypersomnia,
hypersomnolence, sedation, and somnolence

Table 17: Incidence of EPS Compared to Placebo in Schizophrenia
Studies

                                          LATUDA

                       Placebo    20 mq/day   40 mg/day
                       (N=708)      (N=71)      (N=487)
Adverse Event Term       (%)         (%)          <%)

All EPS events            9           10           21
All EPS events,           6           6            11
  excluding
  Akathisia/
  Restlessness
  Akathisia               3           6            11
  Dystonia *              <1          0            4
  Parkinsonism **         5           6            9
  Restlessness            1           1            3

                                      LATUDA

                       80 mg/day   120 mg/day   160 mg/day
                        (N=538)      (N=291)      (N=121)
Adverse Event Term        (%)          <%)          (%)

All EPS events             23           39           20
All EPS events,            12           22           13
  excluding
  Akathisia/
  Restlessness
  Akathisia                12           22           7
  Dystonia *               5            7            2
  Parkinsonism **          8            17           11
  Restlessness             1            3            2

Note: Figures rounded to the nearest integer

* Dystonia includes adverse event terms: dystonia, oculogyric crisis,
oromandibular dystonia, tongue spasm, torticollis, and trismus

** Parkinsonism includes adverse event terms: bradykinesia, cogwheel
rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle
rigidity, parkinsonism, psychomotor retardation, and tremor

Table 18: Incidence of EPS Compared to Placebo in the Monotherapy
Bipolar Depression Study

                                                 LATUDA

                        Placebo   20 to 60 mg/day   80 to 120 mg/day
                        (N=168)       (N=164)            (N=167)
Adverse Event Term        (%)           (%)                (%)

All EPS events             5             12                 20
All EPS events,            2             5                  9
  excluding Akathisia
  /Restlessness
  Akathisia                2             8                  11
  Dystonia *               0             0                  2
  Parkinsonism **          2             5                  8
  Restlessness             <1            0                  3

Note: Figures rounded to the nearest integer

* Dystonia includes adverse event terms: dystonia, oculogyric crisis,
oromandibular dystonia, tongue spasm, torticollis, and trismus

** Parkinsonism includes adverse event terms: bradykinesia, cogwheel
rigidity, drooling, extrapyramidal disorder, glabellar reflex
abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor
retardation, and tremor

Table 19: Incidence of EPS Compared to Placebo in the Adjunctive
Therapy Bipolar Depression Studies

                        Placebo         LATUDA
                        (N=334)    20 to 120 mg/day
                          (%)           (N=360)
Adverse Event Term                        (%)

All EPS events             13             24
All EPS events,            9              14
excluding Akathisia/
  Restlessness
  Akathisia                5              11
  Dystonia *               <1              1
  Parkinsonism **          8              13
  Restlessness             <1              4

Note: Figures rounded to the nearest Integer

* Dystonia Includes adverse event terms: dystonia, oculogyric crisis,
oromandibular dystonia, tongue spasm, torticollis, and trismus

** Parkinsonism Includes adverse event terms: bradykinesia, cogwheel
rigidity, drooling, extrapyramidal disorder, glabellar reflex
abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor
retardation, and tremor

Table 20: Serum Creatinine Shifts from Normal at Baseline to High at
Study End-Point In Schizophrenia Studies

Laboratory          Placebo      LATUDA       LATUDA
Parameter           (N=708)    20 mg/day    40 mg/day
                                 (N=71)      (N=487)

Serum Creatinine       2%          1%           2%
Elevated

Laboratory            LATUDA       LATUDA       LATUDA
Parameter           80 mg/day    120 mg/day   160 mg/day
                     (N=538)      (N=291)      (N=121)

Serum Creatinine        2%           5%           7%
Elevated

Table 21: Serum Creatinine Shifts from Normal at Baseline to High at
Study End-Point in a Monotherapy Bipolar Depression Study

                        Placebo        LATUDA             LATUDA
                        (N=168)    20 to 60 mg/day   80 to 120 mg/day
Laboratory Parameter                   (N=164)            (N=167)

Serum Creatinine          <1%            2%                 4%
Elevated

Table 22: Serum Creatinine Shifts from Normal at Baseline to High at
Study End-Point In the Adjunctive Therapy Bipolar Depression Studies

                             Placebo         LATUDA
                             (N=334)    20 to 120 mg/day
Laboratory Parameter                         (N=360)

Serum Creatinine Elevated       2%             4%

Figure 1: Impact of Other Drugs on LATUDA Pharmacokinetics

Interacting drug          PK        Fold Change   Recommendation
                                    and 90% CI

Strong CYP3A4 Inhibitor

Ketoconazole 400 mg/day   Cmax                    Should not be
                                                  coadministered

                          AUC

Moderate CYP3A4
Inhibitor

Diltiazem                 Cmax                    Starting dose =
240 mg/day                                        20 mg

                          AUC                     Maximum dose =
                                                  80 mg

Strong CYP3A4 Inducer

Rifampin 600 mg/day       Cmax                    Should not be
                                                  coadministered

                          AUC

Lithium                   Cmax                    Adjustment
600 mg BID                                        not required

                          AUC

Figure 2: Impact of LATUDA on Other Drugs

Interacting drug     PK        Fold Change   Recommendation
                               and 90% CI
P-gp Substrates

Digoxin              Cmax                    Adjustment
0.25 mg SD                                   not required

                     AUC

CYP3A4 Substrates

Midazolam            Cmax                    Adjustment
5 mg SD                                      not required
                     AUC

Oral Contraceptive

Ethinyl Estradiol    Cmax                    Adjustment not
                                             required

                     AUC

Norelgestromin       Cmax                    Adjustment not
                                             required

                     AUC

Lithium              Ctrough                 Adjustment
600mg BID *                                  not required
COPYRIGHT 2017 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CLINICAL EXPERTS IN BIPOLAR DEPRESSION: Perspectives Across Disciplines
Publication:Current Psychiatry
Geographic Code:1USA
Date:Jan 1, 2017
Words:14021
Previous Article:REIGNITE the desire: tackle burnout in psychiatry.
Next Article:Medical psychiatry: the skill of integrating medical and psychiatric care.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters